• 10.Februar 2017 | Epo press release |

    Tracking resistance - new tumor models predict treatment response to anticancer drugs in colon carcinomas

    Together with international colleagues scientists from Berlin found new genetic patterns, which help to predict response in colon cancer.

    go to press release

  • November 2016 | Company news |

    EPO successfully participated at the 28th EORTC-NCI-AACR Symposium 2016 in Munich

    EPO presented several posters at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in November 29 during the Preclinical Model -, the Drug Resistance and Modifiers - and the Animal Models Poster Sessions.

    EPO participated with an own booth, where we showed an overview about our activities and met customers and collaborators.

    Please click on the link to view our poster presentations.

    We are looking forward to meeting you there. Connect with us now or at the meeting to say hello! Contact us or email us directly to schedule.

  • April 2016 | Company news | Our co-worker Maria Rivera successfully finished her PhD thesis

    Colorectal cancer patient-derived xenograft (PDX) models as platform for drug screening, molecular and response analysis

    Within the frame of her work a panel of 49 colon cancer xenografts was established and comprehensively characterized for

    - indentity with original patient specimen
    - expression of EpCAM and p53
    - expression of growth factor receptors and their ligands
    - mutational profiling
    - response to classical cytotoxic and targeted drugs

    These models are now available for further biomarker analysis and development of novel therapies.

  • 01.04.2016 | Company news

    EPO presented two posters at the AACR Annual Meeting 2016 in New Orleans

    Analysis of murine stromal components in patient-derived xenograft (PDX) models of pancreatic cancer

    The poster is online and available for download >>>

    Preclinical model of patient-derived tumor xenograft in humanized mice

    The posters is now online and available for download >>>

  • 29.02.2016 | Company news

    EPO presented at 32. German Cancer Congress in Berlin 24.-27. February 2016

    Main focus of the congress was the personalised medicine and updates to frequent and rare cancer diseases. Two invited talks were given by Iduna Fichtner with the topic “PDX models in biomarker research” and by Annika Wulf-Goldenberg with the title “Humanized models for testing immunotherapeutics”. Two out of six presented posters were chosen as Best of Abstracts. Wolfgang Walther presented “Phase I gene therapy trial for nonviral jet-injection gene transfer of the TNF-alpha expressing minimalistic MIDGE vector in melanoma patients” and Maria Stecklum “Development of a functional humanized immune system in mice by transplantation of human hematopoietic stem cells – a model for immuno-oncology”.

    The posters from the DKK are now online and available for download (PDX-colon). Please contact us if you have any questions.

  • 15.02.2016 | Company news

    EPO presented at the EORTC-PAMM Winter Meeting in Antwerp, 9-12. February 2016

    The EPO Team has participated at the annual EORTC-PAMM Winter meeting in Antwerp, Belgium. During this meeting EPO presented the potential and challenges of the patient-derived tumor models (PDX) for translational research. Furthermore, the latest developments of EPO in the establishment of glioblastoma and of B-cell lymphoma PDX models were presented as short talks during the meeting. The respective posters can be viewed or downloaded by this link.>>>
    PAMM (PDX-lymphoma) - (PDX-glioma)

  • 05.01.2016 | Company news

    January 2016 - EPO collaboration with NexusPharma

    EPO starts strategic collaboration with NexusPharma to foster its market position in the USA.
    see press release ...

  • 05.01.2016 | Company news

    January 2016 - Histopatology service at EPO

    EPO announces a comprehensive histopatology service for experimental in vivo studies. The independent department offers custom-oriented necropsies, tissue processing, preparation of sections, any (immuno) histological staining and evaluation.

Newsletter on / off

Newsletter 5:

EPO at AACR Annual Meeting 2017 in Washington, D.C.
Read more (link)

Newsletter 4:

EPO has developed a large panel of glioma PDX models. Some of them are growing as orthotopic tumors enabling highly sophisticated studies.
Read more (link)

Newsletter 3:

EPO offers ultrasound imaging for the monitoring of tumor growth.
Read more (link)

Newsletter 2:

EPO has available facilities and device for the use of irradiation in vitro and in vivo.
Read more (link)

Newsletter 1:

Besides expertise for the determination of antitumor efficacy EPO has available special technologies for imaging, radiation, biomarker analysis at protein and molecular level.
Here are some examles (link)

2017 © EPO Berlin-Buch GmbH